GSK delivers further progress in Q2 and sets out new priorities for the Group
New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.
US-based molecular diagnostics firm Asuragen has launched the QuantideX qPCR BCR-ABL minor Kit designed to monitor molecular response in patients with chronic myeloid leukaemia (CML).
US-based Sciex Diagnostics has launched a new fully integrated LC-MS solution, Sciex Topaz System, for use in clinical diagnostics.
US-based medical devices maker Qfix has introduced its new ZiFix Abdominal/Thoracic Motion Control System designed to stimulate shallow breathing for the management of internal body motion caused due to respiration.
Cardinal Health has concluded the purchase of Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency business from Medtronic for a total of $6.1bn.
Medication management systems provider Plexus Technology Group (TG) is set to integrate its anaesthesia information management system (AIMS) with medical imaging firm Codonics’ medication safety technology Safe Label System (SLS) for an improved anaesthesia process.
Novo Nordisk’s diabetes drug Victoza is now approved in Europe as the only GLP-1 analogue with a label including prevention of cardiovascular events.
Medtronic’s Canadian subsidiary has launched its new magnetic resonance imaging (MRI) conditional cardiac resynchronisation therapy defibrillators (CRT-Ds)
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.